IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell ...

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

HC Wainwright reissued their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) in a research report sent ...

HC Wainwright reiterated their neutral rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research report sent to ...

H.C. Wainwright initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $58 price target The firm views the company’s lead ...

Looking at options history for Cleanspark CLSK we detected 29 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Michael Klichinsky, PharmD, PhD, Co-founder and Chief ...

On Tuesday, H.C. Wainwright reaffirmed a positive outlook on OKYO Pharma Ltd. (NASDAQ: OKYO), maintaining a Buy rating and a $7.00 price target. Currently trading at $1.10, with a market ...

Delving into the details, we found 70% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we ...

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...

On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $12.00 price target for Grace Therapeutics (NASDAQ:GRCE), which currently trades at $3.45 with a market cap of $35 million. According to ...

will participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. An audio webcast of the event will be available on the Company's ...